Generare
Builds AI-driven molecular design tools to accelerate generation of novel small molecules for drug discovery, aiming to increase molecule output tenfold by 2027.
Overview
Generare develops AI-powered molecular design capabilities to generate large numbers of novel small molecules for drug discovery and molecular R&D. The company positions its platform to serve pharmaceutical and biotechnology teams seeking to expand candidate libraries and accelerate early-stage discovery through higher-throughput generative design. Generare highlights an explicit target to deliver 10x more novel molecules by 2027 as a core commercial and technical objective. In April 2026 the company completed a €20M financing (reported as $20M) co-led by Alven and Daphni, representing the total disclosed funding to date.
Funding History
Alven and Daphni co-lead Generare’s €20M to produce 10x novel molecules by 2027
Frequently Asked Questions
- How much has Generare raised in total?
- Generare has raised a total of $20M across 1 funding round.
- Who are Generare's investors?
- Generare's investors include Undisclosed.
- What does Generare do?
- Generare develops AI-powered molecular design capabilities to generate large numbers of novel small molecules for drug discovery and molecular R&D. The company positions its platform to serve pharmaceutical and biotechnology teams seeking to expand candidate libraries and accelerate early-stage discovery through higher-throughput generative design. Generare highlights an explicit target to deliver 10x more novel molecules by 2027 as a core commercial and technical objective. In April 2026 the company completed a €20M financing (reported as $20M) co-led by Alven and Daphni, representing the total disclosed funding to date.
- Where is Generare headquartered?
- Generare is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
The AI Healthcare sector is one of the most dynamic areas of AI investment in 2026. This report profiles the top-funded startups in the space, their investors, and the market dynamics driving growth.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.